Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment
Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...
Vigil Neuroscience shares rise on positive Alzheimer's trial data
Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 ...
Promising Prospects for Vigil Neuroscience Inc. with VG-3927: A Groundbreaking Oral TREM2 Agonist
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
Pro-Vigil Earns Great Place To Work Certification™ in U.S.
Pro-Vigil, a provider of AI-enabled remote video monitoring and crime deterrence solutions, today announced it has been Certified™ in the U.S. by Great Place To Work®. This year, 74% of Pro-Vigil ...
ETF Daily News1mon
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Decreases By 18.4%
abrdn plc purchased a new stake in shares of Vigil Neuroscience in the third quarter valued at $799,000. Ensign Peak Advisors Inc boosted its position in shares of Vigil Neuroscience by 72.8% in ...